Revolution Medicines, Inc.

DB:42Z Stock Report

Market Cap: €7.1b

Revolution Medicines Management

Management criteria checks 2/4

Revolution Medicines' CEO is Mark Goldsmith, appointed in Nov 2014, has a tenure of 10.08 years. total yearly compensation is $10.41M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth €29.48M. The average tenure of the management team and the board of directors is 6.5 years and 8 years respectively.

Key information

Mark Goldsmith

Chief executive officer

US$10.4m

Total compensation

CEO salary percentage6.1%
CEO tenure10.1yrs
CEO ownership0.4%
Management average tenure6.5yrs
Board average tenure8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Goldsmith's remuneration changed compared to Revolution Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$567m

Jun 30 2024n/an/a

-US$519m

Mar 31 2024n/an/a

-US$484m

Dec 31 2023US$10mUS$631k

-US$436m

Sep 30 2023n/an/a

-US$331m

Jun 30 2023n/an/a

-US$296m

Mar 31 2023n/an/a

-US$259m

Dec 31 2022US$7mUS$607k

-US$249m

Sep 30 2022n/an/a

-US$245m

Jun 30 2022n/an/a

-US$224m

Mar 31 2022n/an/a

-US$208m

Dec 31 2021US$8mUS$581k

-US$187m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$143m

Mar 31 2021n/an/a

-US$126m

Dec 31 2020US$2mUS$554k

-US$110m

Sep 30 2020n/an/a

-US$95m

Jun 30 2020n/an/a

-US$85m

Mar 31 2020n/an/a

-US$71m

Dec 31 2019US$5mUS$504k

-US$62m

Sep 30 2019n/an/a

-US$57m

Dec 31 2018US$1mUS$490k

-US$49m

Compensation vs Market: Mark's total compensation ($USD10.41M) is above average for companies of similar size in the German market ($USD3.34M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Goldsmith (62 yo)

10.1yrs

Tenure

US$10,411,247

Compensation

Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Goldsmith
CEO, President & Chairman10.1yrsUS$10.41m0.41%
€ 29.5m
Jack Anders
Chief Financial Officer6.3yrsUS$3.05m0.029%
€ 2.1m
Margaret Horn
Chief Operating Officer6.2yrsUS$4.39m0.035%
€ 2.5m
Stephen Kelsey
President of Research & Development7.8yrsUS$4.39m0.11%
€ 7.7m
Xiaolin Wang
Executive Vice President of Development6.8yrsUS$3.23m0.015%
€ 1.1m
Martin Burke
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Michael Fischbach
Academic Co-Founder & Member of Scientific Advisory Boardno datano datano data
Kevan Shokat
Academic Co-Founder & Member of Scientific Advisory Board8yrsno datano data
Walter Reiher
Chief Information Officerno datano datano data
Jan Smith
Chief Scientific Officer1.3yrsno datano data
Erin Graves
Senior Director of Corporate Communications & Investor Relationsno datano datano data
Jeff Cislini
Senior VP2.3yrsno data0.0032%
€ 229.7k

6.5yrs

Average Tenure

53yo

Average Age

Experienced Management: 42Z's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Goldsmith
CEO, President & Chairman10.1yrsUS$10.41m0.41%
€ 29.5m
Martin Burke
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Michael Fischbach
Academic Co-Founder & Member of Scientific Advisory Board8.5yrsno datano data
Kevan Shokat
Academic Co-Founder & Member of Scientific Advisory Board8yrsno datano data
Julian Adams
Senior Advisor & Member of Scientific Advisory Board8yrsno datano data
Alexis Borisy
Lead Independent Director10.1yrsUS$510.63k1.39%
€ 98.9m
Eric Gordon
Senior Advisor & Member of Scientific Advisory Board8.5yrsno datano data
John Kuriyan
Senior Advisor & Member of Scientific Advisory Board8yrsno datano data
Lorence Kim
Independent Director2.4yrsUS$489.99k0.036%
€ 2.6m
Thilo Schroeder
Independent Director6.8yrsno data0.45%
€ 32.3m
Elizabeth Anderson
Independent Director9.8yrsUS$483.78k0.025%
€ 1.8m
Trever Bivona
Senior Advisor & Member of Scientific Advisory Board8yrsno datano data

8.0yrs

Average Tenure

52yo

Average Age

Experienced Board: 42Z's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 08:49
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Revolution Medicines, Inc. is covered by 17 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Alec StranahanBofA Global Research
Chris ShibutaniGoldman Sachs